Simone Brogi

Via Bonanno 6
Pisa, 56126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies.

Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies.

Journal: Bioorganic & medicinal chemistry

Published: June 16, 2026

Thiazolidinedione-triazole hybrids: design, synthesis, and biological evaluation as dual inhibitors of α-amylase and aldose reductase with antioxidant activity for antidiabetic therapy.

Thiazolidinedione-triazole hybrids: design, synthesis, and biological evaluation as dual inhibitors of α-amylase and aldose reductase with antioxidant activity for antidiabetic therapy.

Journal: Molecular diversity

Published: May 23, 2026

Quinazolinone-Based PqsR Modulators Suppress Quorum-Sensing-Driven Virulence in Pseudomonas aeruginosa.

Quinazolinone-Based PqsR Modulators Suppress Quorum-Sensing-Driven Virulence in Pseudomonas aeruginosa.

Journal: ACS infectious diseases

Published: February 23, 2026

Selaginella bryopteris-derived silver nanoparticles against ovarian cancer cells: green synthesis, in vitro anticancer activity, and exploratory in silico analysis.

Selaginella bryopteris-derived silver nanoparticles against ovarian cancer cells: green synthesis, in vitro anticancer activity, and exploratory in silico analysis.

Journal: Frontiers in pharmacology

Published: February 20, 2026

Quinazoline-sulfonamide hybrids as multitarget anticancer agents: inhibition of carbonic anhydrase IX/XII isoforms and VEGFR-2 with in vitro and in silico validation.

Quinazoline-sulfonamide hybrids as multitarget anticancer agents: inhibition of carbonic anhydrase IX/XII isoforms and VEGFR-2 with in vitro and in silico validation.

Journal: Molecular diversity

Published: February 18, 2026

Integrated structure-based and fragment-guided design of isonicotinic acid derivatives as potential KDM4A inhibitors: an in silico study.

Integrated structure-based and fragment-guided design of isonicotinic acid derivatives as potential KDM4A inhibitors: an in silico study.

Journal: Journal of computer-aided molecular design

Published: February 15, 2026

Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo.

Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo.

Journal: Journal of medicinal chemistry

Published: January 05, 2026

Discovery of thieno[2,3-d]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model.

Discovery of thieno[2,3-d]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model.

Journal: RSC advances

Published: December 04, 2025

Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.

Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.

Journal: Apoptosis : an international journal on programmed cell death

Published: December 02, 2025

2-Phenylquinolines Exhibit Anti-Severe Acute Respiratory Syndrome Coronavirus-2 Activity Through the Nonstructural Protein 13 Helicase Inhibition.

2-Phenylquinolines Exhibit Anti-Severe Acute Respiratory Syndrome Coronavirus-2 Activity Through the Nonstructural Protein 13 Helicase Inhibition.

Journal: ChemMedChem

Published: November 21, 2025

Pharmacological Investigation of a Novel Resveratrol-like SIRT1 Activator Endowed with a Cardioprotective Profile.

Pharmacological Investigation of a Novel Resveratrol-like SIRT1 Activator Endowed with a Cardioprotective Profile.

Journal: Molecules (Basel, Switzerland)

Published: September 12, 2025

Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR/VEGFR-2 inhibition.

Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR/VEGFR-2 inhibition.

Journal: Bioorganic chemistry

Published: August 18, 2025

Showing 1-12 of 150

Last Updated: 09/26/2026